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Abstract
Background: Non-muscle-invasive bladder cancer (NMIBC) is a high incidence form of bladder cancer (BCa), where
genetic and epigenetic alterations occur frequently. We assessed the performance of associating a FGFR3 mutation
assay and a DNA methylation analysis to improve bladder cancer detection and to predict disease recurrence of
NMIBC patients.
Methods: We used allele specific PCR to determine the FGFR3 mutation status for R248C, S249C, G372C, and Y375C.
We preselected 18 candidate genes reported in the literature as being hypermethylated in cancer and measured
their methylation levels by quantitative multiplex-methylation specific PCR. We selected HS3ST2, SLIT2 and SEPTIN9
as the most discriminative between control and NMIBC patients and we assayed these markers on urine DNA from
a diagnostic study consisting of 167 NMIBC and 105 controls and a follow-up study consisting of 158 NMIBC at
diagnosis time’s and 425 at follow-up time. ROC analysis was performed to evaluate the diagnostic accuracy of
each assay alone and in combination.
Results: For Diagnosis: Using a logistic regression analysis with a model consisting of the 3 markers’ methylation
values, FGFR3 status, age and known smoker status at the diagnosis time we obtained sensitivity/specificity of 97.
6 %/84.8 % and an optimism-corrected AUC of 0.96. With an estimated BCa prevalence of 12.1 % in a hematuria
cohort, this corresponds to a negative predictive value (NPV) of 99.6 %. For Follow-up: Using a logistic regression
with FGFR3 mutation and the CMI at two time points (beginning of the follow-up and current time point), we got
sensitivity/specificity/NPV of 90.3 %/65.1 %/97.0 % and a corrected AUC of 0.84. We also tested a thresholding
algorithm with FGFR3 mutation and the two time points as described above, obtaining sensitivity/specificity/NPV
values of, respectively, 94.5 %/75.9 %/98.5 % and an AUC of 0.82.
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Conclusions: We showed that combined analysis of FGFR3 mutation and DNA methylation markers on urine can
be a useful strategy in diagnosis, surveillance and for risk stratification of patients with NMIBC. These results provide
the basis for a highly accurate noninvasive test for population screening and allowing to decrease the frequency of
cystoscopy, an important feature for both patient quality of life improvement and care cost reduction.
Keywords: Non-muscle-invasive bladder cancer, Urine-based assay, Genetic and Epigenetic DNA biomarkers,
Diagnosis, Surveillance
Abbreviations: ALB, Albumin; AS-PCR, Allele specific-PCR; BCa, Bladder cancer; CIS, Carcinoma in-situ; NMIBC, Non-
muscle invasive bladder cancer; NPV, Negative predictive value; MIBC, Muscle invasive bladder cancer; QM-
MSP, Quantitative multiplex-methylation specific PCR
Background
Bladder cancer (BCa) ranks among the five most common
malignancies worldwide [1]. In a majority of the cases
(more than 80 %), Bca is non-muscle-invasive bladder can-
cer (NMIBC) with low-stage (CIS, pTa, pT1) and low or
high-grade [2]. The pTa tumors are associated with a high
rate of recurrence (50–75 %) but a low probability (5 %) of
progression to lamina propria-invasive (pT1) after resec-
tion, whereas carcinoma in-situ (CIS) may be the most
common precursor of invasive bladder cancer because it
shows a strong tendency to progress (40–50 %) towards
muscle-invasive bladder cancer (MIBC) [3]. Cystoscopy
and urine cytology are the standard exams for diagnosis
and surveillance of NMIBC. The monitoring of NMIBC
patients consists of cystoscopic evaluations performed peri-
odically, making it the most expensive of all cancers [4].
The sensitivity of cystoscopy is, however, limited to the tu-
mors that can be identified visually, and the sensitivity of
cytology is relatively low in low-stage/low-grade tumors
[5]. Therefore, other methods (e.g. NMP22, BTA test,
ImmunoCyt and Urovysion) have been developed to reduce
the need for cystoscopy with a considerable benefit to both
patients and healthcare systems. These noninvasive mo-
lecular tests are not recommended for use in diagnosis and
monitoring of Bca because of their low diagnostic accuracy
[6]. Genetic and epigenetic factors are known to contribute
to the occurrence of BCa [7]. FGFR3 mutations were ob-
served in over 50 % of patients with NMIBC [8] and pro-
posed as a urine prognostic marker for the early diagnosis
and detection of recurrences in low-grade tumors [9, 10].
DNA hypermethylation of the CpG islands located in the
promoter regions of tumor-suppressor genes has been asso-
ciated with tumor development in many human cancers
[11]. Studies have suggested that measurement of the
methylation level in urine sample can aid to early diagnosis
of BCa [12–14]. Several recent works showed that the de-
tection of FGFR3 mutations in combination with methyla-
tion analysis could be a promising method for the sensitive
detection of primary and recurrent NMIBC [15, 16]. The
purpose of this present study is to investigate whether com-
bining methylation measurement of a novel set of DNA
methylation markers (HS3ST2, SEPTIN9 and SLIT2) to
the detection of FGFR3 mutations can lead to the develop-
ment a sensitive/specific urine test for the initial diagnosis
and the surveillance of low, intermediate, and high-risk
NMIBC.
Methods
Study design
As shown in Fig. 1, patients were consecutively and pro-
spectively recruited over a period of time running from
2008 to 2010 on the basis of presenting with a primary
NMIBC tumor (pTa, pT1, CIS, low or high grade). As de-
scribed in [17], NMIBC all patients treated by transureth-
ral resection were eligible, but only those who signed an
informed consent were enrolled with a follow-up of 2 years
(last follow-up sample collected in 2012). Tumor statuses
were histologically confirmed and graded/staged accord-
ing to the TNM guidelines. A patient was considered as
control if the biopsy indicated a benign tissue or, in the
absence of a biopsy, if cystoscopy showed no evidence of
disease (the controls do not belong to the AUVES project
NMIBC cohort). In cases where patients under surveil-
lance were positive for recurrence, they were excluded
from the study to be treated. FGFR3 and methylation as-
says were carried out independently and as a blind test.
Urine collection and patients’ information
Urine samples were obtained from a collection code-named
AUVES (project reference RECF0998-PHRC 2003) across
all 4 participating urology units of public hospitals located
at Paris. The samples’ collection and use were reviewed and
approved by the Paris Bichat-Claude Bernard hospital ethics
committee (approval number: 2004/15). Each urine was col-
lected from the first miction in the morning and before
cystoscopy performed on the same day.
One hundred eighty one patients with a primary NMBIC
tumor were initially included. We retained 167 of those pa-
tients (135 males and 32 females, median age 67 years, range
28–85 years (Fig. 1) as the full set of patients for our study.
For the diagnosis study, the tumor samples came from all
167 of the full set of patients and the control samples came
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from 105 other individuals (52 males and 53 females, me-
dian age 53 years, range 23–81 years). For the surveillance
study, we included 158 out of the 167 patients who had
urine collected in the diagnostic study (126 males and 32 fe-
males, median age 67 years, range 28–84 years), and col-
lected a total of 613 urine samples, so having 158 samples at
the diagnostic time and 455 at further time points of the
follow-up. The demographic and clinico-pathological patient
information is detailed in Tables 1 and 2.
Processing of urine samples for capture and enrichment
of tumor cells
The procedure is detailed in [16]. Briefly, 100 ml of each
urine samples were filtered on a nylon membrane of
11 μm of porosity (Millipore) mounted in the correspond-
ing filter holder (Millipore). Each filter was washed with
cold 1X phosphate-buffered saline (PBS, pH 7.4) and then
removed from the filter holder for DNA isolation. To
avoid saturation, urine sample was passed through the fil-
ter under gentle aspiration by positive force.
Urine DNA isolation
DNA was isolated using the QiAmp DNA Mini kit (Qia-
gen), according to the manufacturer's protocol. The filter
is introduced into a sterile tube in presence of AL lysis
buffer. The DNA solution was incubated in the presence
of proteinase K at 56 °C for at least one 1 h then eluted
in 50 μl of elution buffer. DNA concentration was
Fig. 1 Schematic representation of the study design. For the diagnosis study two series were performed, a Selection set and a Diagnosis set. In
total, 272 urine samples were collected. This set consisted of 167 NMIBC patients and 105 controls. For the surveillance study, we included 158
out of the 167 patients who had urine collected in the diagnostic study, and collected a total of 583 urine samples, so having 158 samples at the
diagnostic time point and 425 at further time points
Roperch et al. BMC Cancer  (2016) 16:704 Page 3 of 9
measured using NanoDrop spectrophotometer and
stored at −80 °C until uses.
FGFR3 mutation analysis
Detection of 4 hotspot mutations of FGFR3, namely
S249C, Y375C, R248C and G372C, was carried out using
allele specific PCR (AS-PCR) in duplex mode (AS-PCR1,
AS-PCR2). AS-PCR1 and AS-PCR2 detect simultan-
eously R248C/G372C and S249C/Y375C respectively, as
checked by using the β-globin gene included as an in-
ternal amplification control. Cycling conditions and
concentrations of all primers and probes are as de-
scribed in [16]. PCR products were separated on capil-
laries in an automatic sequencer (ABI PRISM 3100
Genetic Analyser, Applied Biosystems). GeneScan Ana-
lysis Software (Applied Biosystems) was used for data
analysis.
Identification of best candidate epigenetic markers
We performed literature search to identify hypermethy-
lated genes reported as biomarker candidates to distin-
guish NMIBC patients from healthy individuals. The
search was conducted on the PubMed search engine for
the period of time going from 2000 to 2015 using the
following search key phrase: (“DNA methylation and/or
bladder cancer”) where 499 articles listed. Among these
articles, 66 relevant were identified by the following
inclusion methylation criteria: 1) They had to be ori-
ginal research studies of the relationship between DNA
hypermethylation and bladder cancer; 2) NMIBC cases had
to be diagnosed based on histological biopsy; 3) Control
subjects had to be free of cancer; 4) Candidate hyper-
methylated genes had to be determined by microarrays
or methylation-specific PCR or quantitative MSP from
tissue and/or urine samples. We thus preselected a
panel of 18 candidate genes including COL1A2, DDR1,
DIRAS3, DNASE1L, EYA4, FASTK, HS3ST2, NPY, NTRK3,
PENK, SEMA3B, SEPTIN5, SEPTIN9, SLIT2, SYNE1,
TGFβ1,TWIST1, andWIF1.
Table 1 Clinical characteristics of the 167 patients with initial
diagnosis of NMIBC
Characteristic Case (n = 167) Control (n = 105)
Age, yrs.
Median 67 53
Range 28–85 23–81
Sex, no. (%)
Male 135 (80.8) 52 (49.5)
Female 32 (19.2) 53 (50.5)
Smoking History, no. (%)
Current smoker 38 (22.8) NA
Former smoker 58 (34.7) NA
Non-smoker 67 (40.1) NA
Missing 4 (2.4)
Cytology, no. (%)
Negative/Positive/
Suspicious
123 (73.6)/8 (4.8)/6 (3.6) 105 (100)
Missing 30 (18.0)
Tumor Stage, no. (%)
pTa/pT1/CIS 126 (75.4)/25 (15.0)/6 (3.6) NA
Other 10 (6.0) NA
Tumor Grade, no. (%)
Low/High 100 (59.9)/67 (40.1) NA
Risk Categories, no. (%)
Low/Intermediate/High 40 (24.0)/56 (33.5)/71 (42.5) NA
Table 2 Clinical characteristics of the 158 NMIBC patients under
surveillance
Characteristic Recurrence-free (n = 86) Recurrence (n = 72)
Age, yrs.
Median 67 66
Range 30–84 28–83
Sex, no. (%)
Male 74 (86.1) 52 (72.2)
Female 12 (13.9) 20 (27.8)
Smoking History, no. (%)
Current smoker 25 (29.1) 12 (16.7)
Former smoker 34 (39.5) 22 (30.6)
Non-smoker 26 (30.2) 35 (48.6)
Missing 1 (1.2) 3 (4.1)
Recurrence Rate, no. (%) 72 (45.6)
Time to recurrences, mos.
Median/Range 10/3–24
Follow-up Urine
Analyzed, no.
312 113
Total Urine
Analyzed, no.
398 185
Cytology, no. (%)
Negative/Positive/
Suspicious
67 (77.9)/6 (7.0)/2 (2.3) 50 (69.5)/2 (2.8)/3 (4.1)
Missing 11 (12.8) 17 (23.6)
Tumor Stage, no. (%)
pTa/pT1/CIS 62 (72.1)/14 (16.3)/4 (4.6) 55 (76.4)/11 (15.3)/2 (2.8)
Other 6 (7.0) 4 (5.5)
Tumor Grade, no. (%)
Low/High 48 (55.8)/38 (44.2) 47 (65.3)/25 (34.7)
Risk Categories, no. (%)
Low/Intermediate/
High
23 (26.7)/25
(29.1)/38 (44.2)
15 (20.8)/28
(38.9)/29 (40.3)
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Bisulfite DNA modification and methylation analysis
DNA (50 ng) was chemically modified by sodium bisul-
fite treatment at 50 °C in the dark for 16 h with the EZ
DNA Methylation kit (Zymo Research) and eluted in
28 μl of TE buffer (10 mM Tris-HCl (pH 8.0), 1 mM
EDTA). To quantify the methylation levels in urine sam-
ples, where the DNA amount is often limiting, we used the
quantitative multiplex methylation-specific PCR (QM-
MSP) using the TaqMan MBG probes technology (Life
Technologies), a highly sensitive and specific PCR devel-
oped previously by our team [18]. QM-MSP, were carried
out in a StepOne Plus Real-Time PCR system (Life Tech-
nologies). We used the Universal methylated human DNA
standard (Zymo Research) as a calibrator and positive con-
trol and urine DNA as sample. QM-MSP reactions were
performed in duplicate. In each 20 μL reaction, HS3ST2,
SEPTIN9 and SLIT2 methylated markers and Albumin
(ALB) were amplified with a 1x Kapa Fast Probe (Kapa Bio-
systems), 400 nM primers and 250 nM TaqMan-MGB
probes (Life Technologies). Albumin (ALB) that not con-
taining CpG sites was used for normalizing the DNA
amounts. All primers were designed to have the same an-
nealing temperature (Additional file 1: Table S1). We per-
formed two QM-MSP for co-amplification 6Fam-SEPTIN9
and Vic-ALB (QM-MSP1) and 6Fam-HS3ST2 and Vic-
SLIT2 (QM-MSP2), respectively. The PCR cycling parame-
ters were initial denaturation at 95 °C for 5 min followed by
95 °C for 15 s, 60 °C for 1 min, repeated 48 times. In sup-
plementary data, we showed that QM-MSP gave similar ef-
ficiency (range 99.2–101.4 %) as the quantitative singleplex-
MSP (QS-MSP) allowing to reduce of half the number of
PCR (Additional file 2: Figure S1). The target’s relative level
of methylation (percentage of methylated reference (PMR))
was determined by the “2-ΔΔCt” method were ΔΔCt = (Ct
target - Ct ALB)Control - (Ct target - Ct ALB)Sample.
Assays
Target selection
We first performed a selection series to select the best
methylation targets and to fine-tune our assay, and mea-
sured FGFR3 status and methylation percentage of the
18 genes from the preselected panel on urine DNA from
45 of the 167 NMIBC patients and from the 105 con-
trols. Among those 18 candidate genes, we selected the
genes with the following criteria: 1/having at least 1/3 of
the control results available and 2/the controls’ mean
methylation percent is more than 5 %, and, among those
genes, we chose the 3 having the highest specificity for a
sensitivity of at least 90 %, so obtaining HS3ST2, SEP-
TIN9, and SLIT2.
Studies
For the diagnosis study, we measured the methylation
percentages of HS3ST2, SEPTIN9, SLIT2 (Table 3) and
the FGFR3 status on the 167 NMIBC patients. For the
follow-up study, we assayed the same on the follow-up
urine samples. Thirty samples were not assayable because
of too low DNA yield. The remaining 583 were from 158
NMIBC patients, with 158 samples at diagnosis’ time and
425 urine samples at various time points of the follow-up.
Out of the 425 follow-up urine samples had recurrence
and 353 were recurrence-free, defining recurrence as the
return of BCa after treatment and after a period of time
during which the BCa could not be detected.
Multivariate analysis and further analyses
Diagnosis data
We fit a logistic regression on the data set, using a
model with the 3 markers’ methylation values, FGFR3 sta-
tus, age and known smoker status at the diagnosis time.
Follow-up data. We defined: 1/CMI_0 as the CMI at diag-
nosis’ time (t = 0) and 2/CMI_t as the CMI at monitoring's
time (time t > 0). We fit a logistic regression on the whole
data set using a model with FGFR3 status, CMI_0 and
CMI_t as defined above. Other models, like including the
3 methylation values separately and/or clinical covariates
in the predictors did not show better results for high sen-
sitivity (>90 %). In both computations, we computed ROC
curve and AUC, and subsequently optimism-corrected
AUC by a bootstrap process with 5000 iterations. We used
the ROCR R package [19] in these computations.
We also tested a thresholding algorithm with the FGFR3
mutation and the sum of the three methylation values at
two time points, the diagnosis time and the current time,
devised after noting a clustering of recurrence samples in
visual inspection in one the corresponding graphs. The
details are in Additional file 3.
Results
Performance of FGFR3 assay alone, CMI alone and their
combination to detect tumor stage and histological grade
Table 4A represents the association of positive FGFR3
mutation, together with the methylation status of HS3ST2,
Table 3 Sensitivity and Specificity of the single or multiple
methylation markers in the diagnosis of NMIBC
% Sensitivity (Se) % Specificity (Sp)
Diagnosis set (n =272)
HS3ST2 82.0 (137/167) 21.20 (22/105)
SEPTIN9 90.4 (151/167) 67.6 (71/105)
SLIT2 90.4 (151/167) 18.1 (19/105)
HS3ST2 + SEPTIN9 90.4 (151/167) 72.4 (76/105)
HS3ST2 + SLIT2 90.4 (151/167) 34.3 (36/105)
SEPTIN9 + SLIT2 91.0 (152/167) 71.4 (75/105)
HS3ST2 + SEPTIN9 + SLIT2 90.4 (151/167) 75.2 (79/105)
Note: Performance Se/Sp for either 1/highest Sp with Se > 90 % or 2/highest
Sp if no Se > 90 %
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SEPTIN9, SLIT2, with low-stage and histological grade for
the initial diagnosis of NMIBC. The relative figures for
FGFR3 mutation alone in stage/grade tumors were in
46.0 % pTa, 28.0 % pT1, 16.7 % CIS, 30.0 % other tumor
stages, 53.0 %/23.9 % low/high-grade. (Other tumors were
characterized by pathologists as being NMIBC tumors but
not classified as pTa, pT1 and CIS). We observe that
S249C is the most relevant mutation in pTa/pT1/low/
high-grade, with 69.0 %/42.8 %/62.2 %/66.7 %. The figures
for the methylation CMI alone: We identified 90.5 % pTa,
100 % pT1, 100 % CIS, 90.0 % other tumor stages, 89.0 %/
100 % low/high-grade. Using the combination of FGFR3
mutation and methylation, we showed an increase of sen-
sitivity in the low- stage pTa up to 94.4 %, and in the low-
grade with 94.0 %. Table 4B shows the same as above for
the surveillance of NMIBC. The relative figures for FGFR3
were in 43.6 % pTa, 36.4 % pT1, 50.0 % in other stages,
46.8 %/32.0 % low-/high-grade tumors. As previously ob-
served for the initial diagnosis of NMIBC, S249C is the
most relevant mutation detected in recurrence. For con-
cerns the methylation CMI alone: we identified 89.1 %
pTa, 90.9 % pT1, 100 % CIS, and 50 % in other stages,
85.1 %/96.0 % low-/high-grade tumors. Using the combin-
ation of FGFR3 mutation and methylation, the detection
of recurrence was significantly increased with 96.4 % pTa,
100 % pT1, 100 % CIS, 50.0 % other tumor stages, 93.6 %/
96.0 % low-/high-grade tumors. In summary, we showed a
strong complementarity between FGFR3 assay and methy-
lation assay with sensitivity significantly increased for pTa
low-grade (Table 4A-B).
Multivariate analysis
Diagnosis data
We obtained sensitivity/specificity of 97.6 %/84.8 % and
a AUC of 0.97, which resulted in a corrected AUC of
0.96 (Fig. 2a). With an estimated BCa prevalence of
12.1 % in a hematuria cohort [20], this corresponds to a
NPV of 99.6 %. Follow-up data. We obtained sensitivity/
specificity/NPV of 90.3 %/65.1 %/97.0 % and a corrected
AUC of 0.84 (Fig. 2b).
Accuracy of combined test in the surveillance of patients
at low-, intermediate- or high-risk NMIBC by using our
thresholding algorithm
We obtained sensitivity/specificity/NPV values of, respect-
ively, 94.5 %/75.9 %/98.5 % and an AUC of 0.82 on the
whole surveillance set. For concerns risk stratification: As
shown in Table 2, 158 patients with first NMIBC were
Table 4 Comparison of sensitivities of FGFR3 mutations, methylation, and combined markers according to stage and grade
A. Diagnosis study Primary tumor (n = 167)
Markers Tumor stage, % (no.) Tumor grade, % (no.)
pTa (n = 126) pT1 (n = 25) CIS (n = 6) Other (n = 10) Low (n = 100) High (n = 67)
FGFR3
All mutations 46.0 (58) 28.0 (7) 16.7 (1) 30.0 (3) 53.0 (53) 23.9 (16)
S249C 69.0 (40) 42.8 (3) 62.2 (33) 62.5 (10)
Y375C 13.8 (8) 28.6 (2) 33.3 (1) 17.0 (9) 12.5 (2)
R248C 10.3 (6) 28.6 (2) 100 (1) 33.3 (1) 11.3 (6) 25.0 (4)
G372C 5.2 (3) 5.7 (3)
S249C/R248C 1.7 (1) 1.9 (1)
S249C/Y375C 33.3 (1) 1.9 (1)
Methylation 90.5 (114) 100 (25) 100 (6) 90.0 (9) 89.0 (89) 100 (67)
Combined markers 94.4 (119) 100 (25) 100 (6) 90.0 (9) 94.0 (94) 100 (67)
B. Follow-up study Recurrence (n = 72)
Markers pTa (n = 55) pT1 (n = 11) CIS (n = 2) Other (n = 4) Low (n = 47) High (n = 25)
FGFR3
All mutations 43.6 (24) 36.4 (4) 50.0 (2) 46.8 (22) 32.0 (8)
S249C 58.3 (14) 100 (4) 54.6 (12) 75.0 (6)
Y375C 20.8 (5) 13.7 (3) 25.0 (2)
R248C 16.7 (4) 50.0 (1) 22.7 (5)
G372C 4.2 (1) 4.5 (1)
S249C/R248C 50.0 (1) 4.5 (1)
Methylation 89.1 (49) 90.9 (10) 100 (2) 50.0 (2) 85.1 (40) 96.0 (24)
Combined markers 96.4 (53) 100 (11) 100 (2) 50.0 (2) 93.6 (44) 96.0 (24)
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enrolled in the follow-up study and categorized with regard
to the risk of recurrence. The patients’ distribution among
low/intermediate/high-risk group was 24.0 %/33.6 %/
42.4 %. The 72 patients with recurrence were distrib-
uted in low/intermediate/high-risk group as 20.8 %/
38.9 %/40.3 %. The 68 correctly predicted recurrences
were distributed in intermediate/high-risk group as 93.3 %/
92.9 %/96.6 %, which again indicates higher propensity of
our test to detect high-risk patients.
Discussion
In this present study, we present a set of markers for a
new noninvasive urine testing affording, to our know-
ledge, the best accuracy for initial diagnosis, surveillance,
and risk stratification of NMIBC patients. With a high
sensitivity and high NPV, our set of markers is useful for
avoiding biopsies and decreasing the frequency of cysto-
scopic surveillance, thereby allowing for both patient
quality of life improvement and cost reduction. Andersson
and co-workers showed that the exfoliation of tumor cells
into the urine depends on tumor characteristics such as
size, stage, grade, and that the filtration of urine samples,
as compared to the centrifugation step, increased the diag-
nostic accuracy of BCa [21]. This observation could be
due to the removal of contaminant leucocytes that are
smaller size than bladder cells, and this size difference
could be exploited to enrich samples for tumor cells. In
order to optimize the accuracy of our combined test, we
chosen to perform the same procedure of urine samples
filtration.
FGFR3 is a transmembrane tyrosine kinase receptor
that binds fibroblast growth factors. Rieger-Christ [22]
and Oers [23] showed an overall frequency of FGFR3
mutations in urine samples for pTa low-grade NMIBC,
ranging 43 % to 62 % and confirmed with our two stud-
ies (53.0 % in the primary tumor and 46.8 % in detection
of early recurrence). As it has been demonstrated by
Zuiverloon [24], sensitivity for FGFR3 assay is correlated
with the number of shed low-grade tumor cells. He also
showed that low-grade tumors are less likely to shed
many cells into the urine as their high-grade counter-
parts because the high-grade tumors have weaker inter-
cellular attachments with in consequence the difficulty
to detect the FGFR3 mutations. As has been shown by
the author, a 24-h collection urines would optimize per-
formance in pTa low-grade tumors and thereby increase
the sensitivity of FGFR3 assay. Consequently, we are
likely to have underestimated the FGFR3 assay sensitiv-
ity, performed on a simple urine sample (100 ml). It has
been shown that high-risk tumors, generally, have gener-
ally more hypermethylated genes than low-risk groups
[25]. Consistent with all these observations, we showed
the existence of a strong complementarity between de-
tection of FGFR3 mutations and methylation analysis of
HS3ST2, SEPTIN9 and SLIT2 genes and that their com-
plementarity has afforded the best diagnostic accuracy
for low-risk NMIBC. HS3ST2, a heparin sulfate sulfotrans-
ferase, is expressed predominantly in brain and may play a
role in the nervous system [26]. Silencing of the HS3ST2
gene by promoter hypermethylation has been observed in
a variety of cancers [27–29], such as BCa [12]. The SEP-
TIN9 gene encodes a member of the conserved septin
family of GTP-binding protein that function in key pro-
cesses including vesicle trafficking, apoptosis, cytoskeletal
A B
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1 - Sp
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Fig. 2 a ROC curve of the diagnosis study, using a logistic regression analysis based on presence/absence of FGFR3 mutation and the CMI of
HS3ST2, SEPTIN9, and SLIT2. b ROC curve for the recurrence study, using a logistic regression analysis based on FGFR3 mutation CMI_t and CMI_0
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remodelling and cell division [30]. SEPTIN9 plays a role in
multiple cancers including ovarian, prostate and breast
cancer as either an oncogene or a tumor suppressor gene
[31]. Hypermethylation of SEPTIN9 has been observed
also in colorectal cancer (CRC) and a commercially avail-
able assay for that marker has been developed by the Epige-
nomics company, affording a sensitivity of 70 % for a
specificity of 81 % [32]. As it has been observed for HS3ST2
methylated gene, we showed its informativeness in NMIBC.
The SLIT gene family is a recently characterized family of
secreted repellents in axon guidance and neuronal migra-
tion during the development of the central nervous system
[33]. Several studies have showed that SLIT2, a tumor sup-
pressor gene, is epigenetically silenced by hypermethylation
of the promoter region in many tumors [34–37], and re-
cently in bladder urothelial carcinoma [12]. While the case
for informativeness of the methylation and mutation status
of well-chosen biomarkers is clearly shown by the literature
and our results, we should also mention the considerable
potential that the next-generation sequencing (NGS) is
showing as compared to previous techniques. This has
been highlighted by Ward and colleagues for the detection
of low frequency FGFR3 and TERT mutations in the urine
of BCa patients from a few nanograms of DNA [38].
Conclusions
We showed that our noninvasive urinary test, combining
the use of genetic and epigenetic alterations, is at the same
time highly sensitive and highly specific in diagnosis, sur-
veillance and can improve risk stratification of NMIBC
patients. In the surveillance of NMIBC two directions of
use are possible: (1) with low-risk tumors one could re-
duce the frequency of follow-up cystoscopies, providing a
major benefit on the patient’s life quality as well as a posi-
tive effect on the medical costs, and (2) with intermediate
or high-risk tumors, it could provide earlier detection of
tumor recurrence, resulting in improved patient survival.
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